Phase I study of a weekly 1h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma

Strumberg, Dirk; Erhard, J.; Harstrick, A.; Klaassen, U.; Müller, Christine H.; Eberhardt, W; Wilke, H.; Seeber, S.

doi:10.1016/s0959-8049(98)00054-9

Cited by 26 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Recent clinical trials have demonstrated the advantage of Ptx in combination with other anticancer agents in treatment of hepatocellular carcinoma. 4,5 However, the therapeutic response of Ptx is often associated with severe side effects caused by its nonspecific cytotoxic effects and special solvents (Cremophor EL ® ). 6,7 Therefore, it becomes the focus in the field of cancer therapy to search novel strategies in order to achieve higher antitumor efficacy of Ptx.…”

Section: Introductionmentioning

confidence: 99%

Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer

Li¹,

Xu²,

Dai³

et al. 2012

IJN

View full text Add to dashboard Cite

Paclitaxel (Ptx), one of the most widely used anticancer agents, has demonstrated extraordinary activities against a variety of solid tumors. However, the therapeutic response of Ptx is often associated with severe side effects caused by its nonspecific cytotoxic effects and special solvents (Cremophor EL ® ). The current study reports the stable controlled release of Ptx/tetrandrine (Tet)-coloaded nanoparticles by amphilic methoxy poly(ethylene glycol)-poly(caprolactone) block copolymers. There were three significant findings. Firstly, Tet could effectively stabilize Ptxloaded nanoparticles with the coencapsulation of Tet and Ptx. The influence of different Ptx/Tet feeding ratios on the size and loading efficiency of the nanoparticles was also explored. Secondly, the encapsulation of Tet and Ptx into nanoparticles retains the synergistic anticancer efficiency of Tet and Ptx against mice hepatoma H22 cells. Thirdly, in the in vivo evaluation, intratumoral administration was adopted to increase the site-specific delivery. Ptx/Tet nanoparticles, when delivered intratumorally, exhibited significantly improved antitumor efficacy; moreover, they substantially increased the overall survival in an established H22-transplanted mice model. Further investigation into the anticancer mechanisms of this nanodelivery system is under active consideration as a part of this ongoing research. The results suggest that Ptx/Tet-coloaded nanoparticles could be a potential useful chemotherapeutic formulation for liver cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer

Li¹,

Xu²,

Dai³

et al. 2012

IJN

View full text Add to dashboard Cite

show abstract

“…Maximum-tolerated doses of paclitaxel varied, ranging from 80 to 175 mg/m 2 in some phase I studies [11, 12, 13, 14, 15, 16, 17, 18]. Assuming consecutive outpatient therapy, we selected a relatively low dose of paclitaxel, 80 mg/m 2 , and set out a regimen of weekly administration for 3 weeks with 1 week off.…”

Section: Discussionmentioning

confidence: 99%

“…Only a few studies have addressed the optimum dose of paclitaxel with respect to weekly administration as a monotherapy for NSCLC. Weekly administration of 70–175 mg/m 2 paclitaxel has been examined for 3–6 weeks [11, 12, 13]. Based on previous studies, 80 mg/m 2 paclitaxel per week was judged appropriate for outpatients in terms of safety and clinical effect [9, 10, 14].…”

Section: Introductionmentioning

confidence: 99%

Phase II Trial of Weekly Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer

Yasuda

Igishi²,

Kawasaki³

et al. 2003

Oncology

View full text Add to dashboard Cite

Objective: New effective therapy is desirable for outpatients with advanced non-small-cell lung cancer (NSCLC). Fractionated administration of paclitaxel may be less toxic and more active against NSCLC. The aim of this study was to evaluate the activity and toxicity of weekly paclitaxel therapy for chemotherapy-naive NSCLC. Methods: Patients with pathological or cytological diagnosis of NSCLC, measurable lesions, and no prior therapy were enrolled. We administered weekly infusions of 80 mg/m² paclitaxel 3 times in a 4-week cycle. In the absence of progressive disease or intolerable toxicity, we treated each patient for a minimum of four cycles. Results: Of 35 patients enrolled, 17 patients achieved partial response, although no complete responses were observed (response rate 49%; 95% confidence interval 32–66%). The median survival time was 55 weeks (range 6–93 weeks). Grade 3 or 4 leukopenia occurred in only 1 patient (3%). Neurotoxicity was the most frequent adverse effect (grades 1 and 2, 26 and 3%, respectively). Serious toxicity, observed in 2 patients (6%), was interstitial pneumonia, and 1 patient died from sequela. Conclusion: Low-dose weekly paclitaxel is a promising therapy for advanced NSCLC with high effectiveness and low toxicity.

show abstract

“…In a phase-I trial [36] a weekly schedule of paclitaxel was tested in 16 patients with documented progression of unresectable HCC. Paclitaxel was given as a 1-hour infusion on days 1, 8, 15, 22, 29 and 36 representing one treatment cycle.…”

Section: Monotherapy With Taxolsmentioning

confidence: 99%

Systemic Treatment of Hepatocellular Carcinoma

Treiber¹

2001

Dig Dis

View full text Add to dashboard Cite

Systemic treatment for hepatocellular carcinoma is indicated in locally advanced or metastatic disease. Monochemotherapies have yielded unsatisfactory results with response rates of around 20% but survival is often not improved. Polychemotherapies may induce complete responses but have substantial toxicity and are limited to selected patients with preserved liver function. Hormonal treatment with tamoxifen is ineffective while megestrol has shown an improvement in quality of life. Octreotide can be given even in cases of impaired liver function, has also a favorable side effect profile and can lead to disease stabilization. Adjuvant therapy with interferon is indicated after successful liver resection or transplantation in patients with chronic viral hepatitis, the role of interferon in other indications or in combination with chemotherapy remains to be determined.

show abstract

Phase I study of a weekly 1h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma

Cited by 26 publications

References 7 publications

Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer

Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer

Phase II Trial of Weekly Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer

Systemic Treatment of Hepatocellular Carcinoma

Contact Info

Product

Resources

About